Focuses on developing small molecule drug to treat brain tumour metastasis
Aimed to solve brain tumour metastasis problem and currently chose B-Raf & MEK as targets
ABM Therapeutics, Inc.
Developing therapeutics for genetically associated diseases
Developing novel drugs, GCS inhibitors(small molecule), for genetically-associated human diseases; such as several lysosomal storage diseases(LSD): GBA associated PD, PKD, etc.
Therapeutics company with a disruptive patient based discovery platform
First-in-class drug discovery to cure Neurodegenerative Diseases including Lou Gehrig's Disease (ALS) and Frontotemporal Dementia (FTD)
HAMC delivery platform for a wide range of treatments from stem cells to small molecules in vivo
Injected HAMC into the tissue, gelation occurs and forms local storage to maintain local concentrations while minimizing systemic exposure
Leading clinical development and commercial platform of innovative drugs for lipid metabolism
Addressing the Treatment Gap in Chronic Kidney Disease (CKD)
There is a significant treatment gap in glucose management for chronic kidney disease (CKD) patients.
First innovative drug for chronic constipation & opioid-induced constipation with new targets and mechanisms
Targeted inhibit DGAT1, preventing the absorption of fatty acids; fatty acids in the stomach and intestines rich in water and electrolytes, promoting defecation
First new drug for Sepsis treatment, brand new targets and drug mechanisms
PCSK9 monoclonal antibody promotes LDL clearance of pathogens by inhibiting PCSK9 activity
ApoE mimic peptide: innovative drugs to treat hypertriglyceridemia, homozygous familial hypercholesterolemia (HoFH), sepsis and acute pancreatitis
Anji Pharmaceuticals Inc.
Focusing on therapeutic development to treat the root cause of hyperuricemia and gout The AR882(for Hyperuricemia and gout) is on the Phase 1 Australia, Phase 1 US and Phase 2 New Zealand.
Arthrosi Therapeutics, Inc
Bonti, a biotech and pharmaceutical company with phase II research and development lead by world-class neurotoxin experts. It is headquartered in Newport Beach, California, USA. Bonti focuses on the development of a unique new neurotoxin-driven therapy that would be used in the beauty industry or to address therapeutic symptoms where it will satisfy unmet needs in existing markets.